• Glial-cell expert Ben Barres dies

    The Stanford neuroscientist’s research focused on the cells in the brain that aren’t nerve cells. Collectively called glia, these “other” cells play a central role in sculpting and maintaining the brain’s wiring diagram.

  • Three named to National Academy of Inventors

    Helen Blau, Stanley Cohen and H. Tom Soh are being honored for their work in creating inventions that have improved the quality of life and welfare of society.

  • Screen could reveal immunotherapy targets

    Stanford scientists have developed a biochemical screen that identifies molecules critical to immunotherapy for a host of diseases, including cancer.

  • Pre-approved drugs tapped for rare eye disease

    By identifying proteins abnormally expressed by patients with a rare eye disease, Stanford researchers were able to identify existing drugs that could be used to treat symptoms.

  • Living with a rare eye disease

    One member of an Iowa family with a rare, blinding eye condition described her experience with the disease.

  • Brain zap saps destructive urges

    A characteristic electrical-activity pattern in a key brain region predicts impulsive actions just before they occur. A brief electrical pulse at just the right time can prevent them, Stanford scientists have found.

  • Moms’ blood sugar affects fetal heart

    Elevated maternal blood sugar when the fetal heart is forming has been linked to a heightened risk for congenital heart defects, according to a new Stanford study.

  • Drug blocks several mosquito-borne viruses

    A new Stanford study details how to shut off proteins in mammalian cells to keep viruses such as Zika, dengue and West Nile from replicating in them.

  • Multiple food allergies treated safely

    Combining an antibody drug, omalizumab, with a procedure to desensitize children to multiple food allergies is safe and effective, according to a new study by Stanford researchers.

  • Drug for disorder sparks ethical concerns

    Medical experts at Stanford and their colleagues at several other universities have raised ethical questions about the way a treatment for spinal muscular atrophy is being used.

2024 ISSUE 1

Psychiatry’s new frontiers